Sam Brusco, Associate Editor05.11.22
BD (Becton, Dickinson and Company) and Babson Diagnostics expanded their strategic partnership to move blood sample collection into new care settings, including blood collection at home for diagnostic testing.
The two firms have collaborated since 2019 on creating a capillary blood collection and testing system that’s now in advanced development. The system will allow lab-quality, small-volume capillary blood collection at retail settings by employees with no prior blood collection experience.
The expanded agreement continues research and development to enable self-collection, mobile services, and at-home collection. BD and Babson will also expand possible blood tests through small-volume collection beyond tests oriented for primary care, as well as develop diagnostics for pediatric use.
"Today's agreement expands our long-standing partnership with BD and builds on our shared passion of making convenient blood testing accessible to all, not only in the U.S., but also globally," David Stein, CEO of Babson Diagnostics told the press. "Extending the medical home is critical in today's health care environment. We believe that retail convenience is perfect for today's consumer, but because the Babson service is well-suited to many settings with no need for a phlebotomist and an easier collection experience, we see many opportunities for future expansion."
Babson and BD are advancing development of the blood testing ecosystem, which includes BD’s next-gen capillary collection technology and Babson’s automated sample-handling and analytical technologies.
The partnership combines BD’s next-gen capillary collection tech and Babson’s automated sample-handling and analytical tech. Working together these components can make blood testing using one-tenth the sample volume of traditional venipuncture possible without sacrificing quality, accuracy, or the number and types of possible tests.
"This is a paradigm-shifting solution that addresses multiple unmet needs within the current health care system," said Brooke Story, BD’s president of Integrated Diagnostics Solutions. "Because it is less invasive and more convenient than the traditional venous blood draw method, capillary blood collection may lead to an improved patient experience, which in turn could help health care providers see better compliance among patients for routine blood testing."
The two firms have collaborated since 2019 on creating a capillary blood collection and testing system that’s now in advanced development. The system will allow lab-quality, small-volume capillary blood collection at retail settings by employees with no prior blood collection experience.
The expanded agreement continues research and development to enable self-collection, mobile services, and at-home collection. BD and Babson will also expand possible blood tests through small-volume collection beyond tests oriented for primary care, as well as develop diagnostics for pediatric use.
"Today's agreement expands our long-standing partnership with BD and builds on our shared passion of making convenient blood testing accessible to all, not only in the U.S., but also globally," David Stein, CEO of Babson Diagnostics told the press. "Extending the medical home is critical in today's health care environment. We believe that retail convenience is perfect for today's consumer, but because the Babson service is well-suited to many settings with no need for a phlebotomist and an easier collection experience, we see many opportunities for future expansion."
Babson and BD are advancing development of the blood testing ecosystem, which includes BD’s next-gen capillary collection technology and Babson’s automated sample-handling and analytical technologies.
The partnership combines BD’s next-gen capillary collection tech and Babson’s automated sample-handling and analytical tech. Working together these components can make blood testing using one-tenth the sample volume of traditional venipuncture possible without sacrificing quality, accuracy, or the number and types of possible tests.
"This is a paradigm-shifting solution that addresses multiple unmet needs within the current health care system," said Brooke Story, BD’s president of Integrated Diagnostics Solutions. "Because it is less invasive and more convenient than the traditional venous blood draw method, capillary blood collection may lead to an improved patient experience, which in turn could help health care providers see better compliance among patients for routine blood testing."
